Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue JNCI: Journal of the National Cancer Institute Année : 2017

Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients

Claire Lethrosne
  • Fonction : Auteur
Nicolas Pourel
  • Fonction : Auteur
Olivier Molinier
  • Fonction : Auteur
Yoann Pointreau
  • Fonction : Auteur
Julien Domont
  • Fonction : Auteur
Pierre Tremolieres
  • Fonction : Auteur
Thibaut Lizee
  • Fonction : Auteur
Thierry Urban
  • Fonction : Auteur
Claude El Khouri
  • Fonction : Auteur
Alexandre Charron
  • Fonction : Auteur
Anne-Lise Septans
Magali Balavoine
  • Fonction : Auteur
Sébastien Landry
  • Fonction : Auteur
Philippe Solal-Celigny
  • Fonction : Auteur

Résumé

Background: The use of web-based monitoring for lung cancer patients is growing in interest because of promising recent results suggesting improvement in cancer and resource utilization outcomes. It remains an open question whether the overall survival (OS) in these patients could be improved by using a web-mediated follow-up rather than classical scheduled follow-up and imaging. Methods: Advanced-stage lung cancer patients without evidence of disease progression after or during initial treatment were randomly assigned in a multicenter phase III trial to compare a web-mediated follow-up algorithm (experimental arm), based on weekly self-scored patient symptoms, with routine follow-up with CT scans scheduled every three to six months according to the disease stage (control arm). In the experimental arm, an alert email was automatically sent to the oncologist when self-scored symptoms matched predefined criteria. The primary outcome was OS. Results: From June 2014 to January 2016, 133 patients were enrolled and 121 were retained in the intent-to-treat analysis; 12 deemed ineligible after random assignment were not subsequently followed. Most of the patients (95.1%) had stage III or IV disease. The median follow-up was nine months. The median OS was 19.0 months (95% confidence interval [CI] = 12.5 to non-calculable) in the experimental and 12.0 months (95% CI = 8.6 to 16.4) in the control arm (one-sided P = .001) (hazard ratio = 0.32, 95% CI = 0.15 to 0.67, one-sided P = .002). The performance status at first detected relapse was 0 to 1 for 75.9% of the patients in the experimental arm and for 32.5% of those in the control arm (two-sided P \textless .001). Optimal treatment was initiated in 72.4% of the patients in the experimental arm and in 32.5% of those in the control arm (two-sided P \textless .001). Conclusions: A web-mediated follow-up algorithm based on self-reported symptoms improved OS due to early relapse detection and better performance status at relapse.

Dates et versions

hal-01611175 , version 1 (05-10-2017)

Identifiants

Citer

Fabrice Denis, Claire Lethrosne, Nicolas Pourel, Olivier Molinier, Yoann Pointreau, et al.. Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients. JNCI: Journal of the National Cancer Institute, 2017, 109 (9), pp.djx029. ⟨10.1093/jnci/djx029⟩. ⟨hal-01611175⟩
517 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More